{"transactions":[{"id":683716,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Series F Warrant (Right to Buy)","published_at":"2026-08-18T21:21:39.000Z","date":"2026-08-16","kind":"grant","planned":false,"acquired":true,"shares":102040,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $1.47."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire two years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire two years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."}],"balance_after":102040,"derivative":{"exercise_price":1.47,"underlying":"Common Stock","underlying_shares":102040},"source":{"system":"sec-edgar","filing":"0001493152-26-039046","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000149315226039046/ownership.xml","form_type":"4"}},{"id":683715,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Series E Warrant (Right to Buy)","published_at":"2026-08-18T21:21:39.000Z","date":"2026-08-16","kind":"grant","planned":false,"acquired":true,"shares":102040,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $1.47."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire five years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire five years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."}],"balance_after":102040,"derivative":{"exercise_price":1.47,"underlying":"Common Stock","underlying_shares":102040},"source":{"system":"sec-edgar","filing":"0001493152-26-039046","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000149315226039046/ownership.xml","form_type":"4"}},{"id":683714,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Common Stock","published_at":"2026-08-18T21:21:39.000Z","date":"2026-08-16","kind":"grant","planned":false,"acquired":true,"shares":102040,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $1.47."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire five years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."}],"balance_after":232463,"source":{"system":"sec-edgar","filing":"0001493152-26-039046","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000149315226039046/ownership.xml","form_type":"4"}},{"id":947033,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T01:00:06.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date."}],"balance_after":18000,"derivative":{"exercise_price":2.18,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001493152-26-000701","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000149315226000701/ownership.xml","form_type":"4"}},{"id":958315,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Warrant (Right to Buy)","published_at":"2025-12-30T00:53:09.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":7874,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"shares","element":"transactionShares","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."}],"balance_after":7874,"derivative":{"exercise_price":2.04,"underlying":"Common Stock","underlying_shares":7874},"source":{"system":"sec-edgar","filing":"0001493152-25-029470","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000149315225029470/ownership.xml","form_type":"4"}},{"id":958314,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Warrant (Right to Buy)","published_at":"2025-12-30T00:53:09.000Z","date":"2025-12-23","kind":"disposition_to_issuer","planned":false,"acquired":true,"shares":7874,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"shares","element":"transactionShares","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the \"old\" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."}],"balance_after":0,"derivative":{"exercise_price":12.7,"underlying":"Common Stock","underlying_shares":7874},"source":{"system":"sec-edgar","filing":"0001493152-25-029470","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000149315225029470/ownership.xml","form_type":"4"}},{"id":958313,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Series D Warrant (Right to Buy)","published_at":"2025-12-30T00:53:09.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":122549,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock. The purchase price per share and accompanying warrants was $2.04."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $2.04."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire two years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire two years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."}],"balance_after":122549,"derivative":{"exercise_price":2.04,"underlying":"Common Stock","underlying_shares":122549},"source":{"system":"sec-edgar","filing":"0001493152-25-029470","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000149315225029470/ownership.xml","form_type":"4"}},{"id":958312,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Series C Warrant (Right to Buy)","published_at":"2025-12-30T00:53:09.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":122549,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock. The purchase price per share and accompanying warrants was $2.04."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $2.04."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire five years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire five years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."}],"balance_after":122549,"derivative":{"exercise_price":2.04,"underlying":"Common Stock","underlying_shares":122549},"source":{"system":"sec-edgar","filing":"0001493152-25-029470","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000149315225029470/ownership.xml","form_type":"4"}},{"id":958311,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Common Stock","published_at":"2025-12-30T00:53:09.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":122549,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the \"Private Placement\"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Each share of common stock was purchased together with (i) a series C warrant to purchase one share of common stock and (ii) a series D warrant to purchase one share of common stock. The purchase price per share and accompanying warrants was $2.04."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of common stock and accompanying warrants was $2.04."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025."}],"balance_after":130423,"source":{"system":"sec-edgar","filing":"0001493152-25-029470","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000149315225029470/ownership.xml","form_type":"4"}},{"id":1296496,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"officer":true,"officer_title":"SVP, CFO"}}],"security":"Warrant (Right to Buy)","published_at":"2025-01-23T22:03:18.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":78741,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of Common Stock and accompanying Warrant was $1.27."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants issued in the private placement. The Warrant will expire five years from the effective date of stockholder approval. The Warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants issued in the private placement. The Warrant will expire five years from the effective date of stockholder approval. The Warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions."}],"balance_after":78741,"derivative":{"exercise_price":1.27,"underlying":"Common Stock","underlying_shares":78741},"source":{"system":"sec-edgar","filing":"0001654954-25-000692","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000165495425000692/section16.xml","form_type":"4"}},{"id":1296495,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"officer":true,"officer_title":"SVP, CFO"}}],"security":"Common Stock","published_at":"2025-01-23T22:03:18.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":78741,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchase price per share of Common Stock and accompanying Warrant was $1.27."}],"balance_after":78741,"source":{"system":"sec-edgar","filing":"0001654954-25-000692","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000165495425000692/section16.xml","form_type":"4"}},{"id":1303569,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"officer":true,"officer_title":"SVP, CFO"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-14T23:50:42.000Z","date":"2025-01-13","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"(1)\tThe shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date."}],"balance_after":20000,"derivative":{"exercise_price":1.38,"expiration_date":"2035-01-12","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001654954-25-000399","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000165495425000399/section16.xml","form_type":"4"}},{"id":1685711,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"officer":true,"officer_title":"SVP, CFO"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-06T02:00:36.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the\n12 month anniversary of the grant date."}],"balance_after":50000,"derivative":{"exercise_price":0.6099,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001654954-24-000291","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000165495424000291/section16.xml","form_type":"4"}},{"id":2063045,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"officer":true,"officer_title":"SVP, CFO"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-05T21:06:29.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date."}],"balance_after":100000,"derivative":{"exercise_price":0.31,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001654954-23-000147","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000165495423000147/section16.xml","form_type":"4"}},{"id":2444464,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-06T00:15:17.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 40% upon the 12 month anniversary of the grant date, and will vest as to 60% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date."}],"balance_after":30000,"derivative":{"exercise_price":1.88,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000905718-22-000050","document":"dermata_fm4jan32022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000090571822000050/dermata_fm4jan32022.xml","form_type":"4"}},{"id":2583853,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":22295,"kind":"person","name":"Van Hoose Kyri K.","position":1,"cik":"0001860885","reported_name":"Van Hoose Kyri K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2021-09-02T00:32:02.000Z","date":"2021-09-01","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 48 equal monthly installments commencing October 1, 2021."}],"balance_after":75000,"derivative":{"exercise_price":5.39,"expiration_date":"2031-09-01","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000905718-21-001165","document":"dermata_fm4sep121.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860885/000090571821001165/dermata_fm4sep121.xml","form_type":"4"}}]}